eptinezumab

all catalysts(0)

nothing on the calendar yet

News(5)

• New guidelines on migraine prevention reflect increasing options for patients
  “There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.
  stat · 1mo ago
• Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
  Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…
  fiercebiotech · 1mo ago
• FDA criticizes Lundbeck for webpages on migraine treatment Vyepti
  The FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent la…
  endpoints · 3mo ago
• Study data convince Lundbeck to push new migraine drug forward
  A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
  biopharma_dive · 4mo ago
• A migraine drugmaker heads to the public markets through reverse merger
  Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
  biopharma_dive · 4mo ago